reports
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
AYI ACUITY BRANDS INC.
WMS ADVANCED DRAINAGE SYSTEMS INC.
VC VISTEON CORPORATION
TRN TRINITY INDUSTRIES INC.
TMO THERMO FISHER SCIENTIFIC INC.
POWI POWER INTEGRATIONS INC.
NEOG NEOGEN CORPORATION
NDSN NORDSON CORPORATION
MKSI MKS INSTRUMENTS INC.
MCHP MICROCHIP TECHNOLOGY INCORPORATED
LEA LEAR CORPORATION
ICLR ICON PLC
FSS FEDERAL SIGNAL CORPORATION
FORM FORMFACTOR INC.
BRKR BRUKER CORPORATION
BMI BADGER METER INC.
AMAT APPLIED MATERIALS INC.
HPQ HP INC.
ACLS AXCELIS TECHNOLOGIES INC.
AMWD AMERICAN WOODMARK CORPORATION
ENTG ENTEGRIS INC.
FBHS FORTUNE BRANDS HOME & SECURITY INC.
KALU KAISER ALUMINUM CORPORATION
TTC TORO COMPANY
VMI VALMONT INDUSTRIES INC.
ITT ITT INC.
AA ALCOA CORPORATION
NOVT NOVANTA INC
IOVA IOVANCE BIOTHERAPEUTICS INC
ADNT ADIENT PLC
ASTL LEGATO MERGER CORP
CR CRANE HOLDINGS CO
ARM ARM HOLDINGS PLC
PRIM PRIME ENERGY P.E. LTD
ANET ARISTA NETWORKS INC
MTAL MAC COPPER LIMITED
ICON plc to Present at Upcoming Investor Conferences
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025 at 8.00 am ET and at the Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025 at 8.30 am ET. Any changes to these events and links to the live webcasts will be posted on the Investor section of our website under “”. About ICON plc ICON plc is a world-leading healthcare intelligence and clinical...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SHAK SHAKE SHACK INC. CLASS A
SKT TANGER FACTORY OUTLET CENTERS INC.
RGR STURM RUGER & COMPANY INC.
POWI POWER INTEGRATIONS INC.
MD MEDNAX INC.
ICLR ICON PLC
HAS HASBRO INC.
CRAI CHARLES RIVER ASSOCIATES INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
AVNW AVIAT NETWORKS
LKO LAKES OIL N.L.
MX MAGNACHIP SEMICONDUCTOR CORP.
BELFB BEL FUSE INC. CL B
LAUR LAUREATE EDUCATION INC. CLASS A
PMTS CPI CARD GROUP
KRYS KRYSTAL BIOTECH INC
SWTX SPRINGWORKS THERAPEUTICS
CSTM CONSTELLIUM SE CLASS A
AM ANTERO MIDSTREAM CORP.
CADL CANDEL THERAPEUTICS INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
ICON Reports Fourth Quarter and Full Year 2024 Results
DUBLIN--(BUSINESS WIRE)-- ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and full year ended December 31, 2024. CEO, Dr. Steve Cutler commented, “ICON’s results in quarter four were in-line with our expectations as we continue to manage through a challenging transition period in our business. Encouragingly, we saw progress in a number of key areas in quarter four. Gross business wins increased 8% sequentially, indicative of a positive, albeit volatile, underlying demand environme...
ICON Portfolio of AI Tools Drives Clinical Trial Efficiencies
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting. ICON has invested significantly in its AI and digital capabilities through the establishment of its AI Centre of Excellence. The centre, which comprises a dedicated team of data scientists, engineers and domain experts, is responsible for developing and deploying AI sol...
ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conferen...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 results after the market closes on Wednesday, February 19, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 20, 2025 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “”. A webcast replay of the confer...
ICON Issues Financial Guidance for Full Year 2025
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025. For the full year 2025, revenue is expected to be in the range of $8,050 - $8,650 million, representing growth of approximately 1% at the midpoint and adjusted earnings per share* is expected to be in the range of $13.00 - $15.00, which is flat over the expected full year 2024 adjusted earnings per share guidance midpoint. Full year 2025 financial guidance excludes any potential share repur...
Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzhe...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer's, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial methodologies. ICON outlines how these innovations, including increased use of biomarkers and innovative tri...
ICON plc to Present at the 43rd Annual J.P. Morgan Healthcare Conferen...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under “”. About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services ...
ICON and Its Employees Celebrated for Excellence in the Field of Clini...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine’s 2024 list of World’s Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in its 2025 list of World’s Best Companies in Sustainable Growth it was featured at number 57 out of 500 companies. ICON was also announced as a winner of the Best Practices Recognition award from the Frost and Sullivan Institute’s Enligh...
ICON Announces Appointment of Chief Operating Officer
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, qu...
ICON Survey Highlights Sustained Investment in AI and Digital R&D Inno...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent global survey of 101 biotech and pharma professionals across Europe and North America to understand the trajectory of AI and digital innovation adoption within clinical research. Respondents revealed that attitudes towards the potential impact of digital tools and AI solutions remain relatively positive. Sponsors’ optimism about their potential to improve R&D productivity has grown +5% since 2019 – the last time ICON conducted a s...
ICON plc to Present at the Jefferies London Healthcare Conference
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:00am GMT. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under “”. About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical resear...
ICON Reports Third Quarter 2024 Results
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the third quarter ended September 30, 2024. CEO, Dr. Steve Cutler commented, “ICON’s results for the third quarter did not meet the expectations we had previously provided due to specific customer and division-level impacts. Our revenue shortfall was attributable to more material headwinds from two large customers undergoing budget cuts and changes in their development model, lower than anticipated vaccine-related activity, and ongoing...
ICON plc Schedules Third Quarter 2024 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the third quarter 2024 after the market closes on Wednesday, October 23, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 24, 2024 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under “”. A webcast replay of the conference call will be available approximately o...
ICON Survey Highlights Scale of Focus on Precision Therapies in Increa...
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a of over 100 professionals engaged in oncology drug development to understand the current state of emerging oncology treatment development, including the associated clinical trial dynamics. Respondents acknowledged that much focus has been accorded to emerging oncology treatments; however, as of yet, there are varied views on the degree to which these precision approaches will improve patient outcomes. Significant investment is made in ca...
ICON plc to Present at the Baird 2024 Global Healthcare Conference
DUBLIN--(BUSINESS WIRE)-- , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird 2024 Global Healthcare Conference on Tuesday, September 10, 2024 at 3:45 pm ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under “”. About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to p...
ICON Announces Appointment of New Chief Financial Officer
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before b...
ICON Reports Second Quarter 2024 Results
DUBLIN--(BUSINESS WIRE)-- (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2024. CEO, Dr. Steve Cutler commented, “ICON delivered positive results in the second quarter, with revenue growth of 5.3% on a constant currency basis year over year, coupled with continued momentum in bookings performance, as backlog increased 10% over quarter two 2023. Adjusted earnings per share grew an impressive 21% year over year, driven by strong margin delivery in addition to the benefits rea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.